Navigation Links
Nuvo announces 2008 fourth quarter and year-end financial results
Date:2/27/2009

MISSISSAUGA, ON, Feb. 27 /PRNewswire-FirstCall/ - Nuvo Research Inc. (TSX: NRI), a Canadian drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, today announced its financial and operational results for the year and the fourth quarter ended December 31, 2008.

    Key Corporate Developments:

    -   Presented positive Phase 3 study results for Pennsaid in a poster
        presentation at the 2008 American College of Rheumatology Scientific
        Meeting in San Francisco

    -   Initiated a warrant incentive program that has the potential to
        generate up to $9 million for the Company

    -   Successfully completed all Pennsaid(R) studies necessary to resubmit
        the application for Pennsaid approval to the United States Food and
        Drug Administration (FDA). The FDA confirmed that it has accepted
        this filing as a complete response to its Approvable Letter for
        Pennsaid dated December 28, 2006 and provided the Company with a date
        of August 5, 2009 (the "PDUFA Date") pursuant to the Prescription
        Drug User Fee Act by which the FDA intends to advise Nuvo on
        Pennsaid's approvability

    -   Announced that the Company's High Throughput Experimentation Platform
        was selected as a 2009 Edison Award Finalist

    "We are highly optimistic about Pennsaid's potential for approval and are
continuing discussions with potential United States licensing partners," said
Henrich Guntermann, President and Chief Executive Officer of Nuvo Research.


    Financial Results:

    (thousands of Canadian dollars)

                      Three months  Three months
                             ended         ended    Year ended    Year ended
                       December 31,  December 31,  December 31,  December 31,
                              2008          2007          2008          2007
    -------------------------------------------------------------------------
    Revenue               $  3,117      $  2,207      $ 10,727      $  7,178
    Net loss              $ (2,413)     $ (3,332)     $(10,552)     $(12,376)
    -------------------------------------------------------------------------

Revenue, consisting of product sales, license fee revenue, and research and other contract revenue, for the three-months ended December 31, 2008 increased 41% to $3.1 million compared with $2.2 million for the three-months ended December 31, 2007. The increase was attributable to many factors including a $0.5 million increase in product sales of both Pennsaid and WF10 based products, the recognition of additional licensing fee revenue and research revenue earned on a collaboration agreement with a Fortune Global 500 company that develops and markets skin care products. For the year, revenue increased 49% to $10.7 million versus $7.2 million. This is primarily due to higher Pennsaid product sales in Greece where 2008 was the first full year of selling the product in this market after its launch during the second quarter of 2007 and an increase of $1.2 million in licensing fee revenue.

Gross margin on product sales was $1.0 million for the three-months ended December 31, 2008 compared to $0.6 million for the comparable quarter in 2007. The increase in gross margin is primarily attributable to a 22% increase in Pennsaid product sales to new quarterly high. For the year, gross margin increased to $3.2 million compared to $1.5 million for the year ending December 31, 2007. The increase in gross margin is primarily attributable to the 37% increase in Pennsaid sales, the 24% increase in WF10 based product sales and significant improvements and efficiencies achieved in the Pennsaid manufacturing process, partially offset by price increases in the raw materials used to compound and package Pennsaid and the strengthening US dollar. The overall gross margin percentage was 40% in 2008 versus 26% in 2007.

Total operating expenses for the three-month period ended December 31, 2008 increased to $4.9 million versus $4.2 million for the three-months ended December 31, 2007. The $0.7 million increase in operating expenses is due to higher research and development expenses, the $0.2 million impairment charge recorded against certain of the Company's intangible assets and increases in selling, general and administrative costs and net interest expense, partially offset by $0.1 million foreign exchange gain in 2008. Total operating expenses for year ended December 31, 2008 were $17.0 million, an increase of 8% compared to $15.7 million for the year ended December 31, 2007. The increase from 2007 relates to an increase in net interest expense and higher research and development spending, offset partially by lower SG&A costs. This highlights the impact of the Company's efforts during the third and fourth quarters of 2007 to focus its resources on research activities rather than administrative costs.

Research and development expenses increased by 17% to $2.5 million for the three months ended December 31, 2008 compared to $2.1 million for the three months ended December 31, 2007. For the year ended December 31, 2008, research and development costs increased 11% to $9.3 million compared to $8.3 million for the year ended December 31, 2007. The majority of the spending in the fourth quarter and the year related to the completion of the Short and Long-Term Studies required to address the conditions raised in the Approvable Letter, costs associated with the Phase 2 trial of WF10 as an adjuvant therapy for pancreatic cancer, the preclinical development of the Company's pipeline candidates and costs relating to expanding the Company's research capabilities in San Diego and a pain advisory conference hosted by the Company.

SG&A expenses increased by 9% to $1.6 million for the three months ended December 31, 2008 compared to $1.5 million for the three months ended December 31, 2007. During the quarter, the impact of lower ongoing personnel costs and the savings associated with closing the Company's international marketing office in Barbados were more than offset by increased spending on business development activities as the Company expanded efforts to sign a U.S. licensee for Pennsaid and higher professional fees related to the Squire Tax Reassessment. For the year ended December 31, 2008, SG&A costs decreased 5% to $5.2 million compared to $5.5 million for the year ended December 31, 2007. The decrease is primarily attributable to activities undertaken during the third and fourth quarters of 2007, including the closure of the Company's international marketing office in Barbados and staff reductions at the corporate head office, offset partially by additional severance costs incurred as the Company continued to strengthen its team, increased spending on business development activities, incurred higher professional fees and the costs related to the Squire Tax Reassessment.

For the three months ended December 31, 2008, the net loss decreased to $2.4 million from $3.3 million for the three months ended December 31, 2007. Included in the results for the quarter is a non-cash gain of $0.9 million from the change in the estimate of the amount of the liability related to the loans from Leadenhall. Excluding the impact of this item, the net loss would have declined slightly to $3.3 million in the current quarter compared to $3.4 million a year ago. For the year ended December 31, 2008, the net loss declined by 15% to $10.6 million from $12.4 million for the year ended December 31, 2007.

Cash and cash equivalents on hand at December 31, 2008 of $15.2 million were $3.7 million less than the $18.9 million at September 30, 2008. The decrease is almost entirely attributable to cash used by operating activities.

Cash used in operating activities of $4.2 million was higher than the $2.7 million used in the three-month comparative period ended December 31, 2007 due primarily to a higher investment in non-cash working capital during the fourth quarter of 2008. The significant investment in non-cash working capital relates primarily to the significant increase in accounts receivable attributable to the achieving record quarterly sales of Pennsaid to Europe during the fourth quarter of 2008. For the year ended December 31, 2008 funds used in operating activities decreased to $9.1 million from $12.3 million.

Detailed financial statements and the MD&A are available at www.nuvoresearch.com or www.sedar.com.

Notice of Annual and Special Meeting

Nuvo will be holding its Annual and Special Meeting of Shareholders on Thursday, April 30, 2009 at 9:00 a.m. (EST) at the Gallery of the Toronto Stock Exchange (TSX) Broadcast & Conference Centre, The Exchange Tower, 130 King Street West, Toronto, Ontario, Canada.

About Pennsaid

Pennsaid is a topical non-steroidal anti-inflammatory drug used for the treatment of osteoarthritis. Pennsaid allows the active ingredient, diclofenac, to be delivered to a specific site via the surface of the skin and thus limits complications associated with systemic delivery. According to published clinical trials, Pennsaid is as effective as the maximum daily dose of comparable oral medication at relieving pain and stiffness associated with osteoarthritis of the knee, as well as improving overall well-being. There are more than 27 million Americans suffering from osteoarthritis, a very painful and debilitating condition, and the United States market for this condition is estimated at US$4 billion annually.

About Nuvo Research Inc.

Nuvo is focused on the research and development of drug products delivered to and through the skin using its topical and transdermal drug delivery technologies. Nuvo's lead product is Pennsaid, a topical non-steroidal anti-inflammatory drug used for the treatment of osteoarthritis. Nuvo intends to leverage its skin-penetrating technologies to create a portfolio of topical and transdermal products targeting a variety of indications.

Nuvo Research Inc. is a publicly traded, Canadian pharmaceutical company headquartered in Mississauga, Ontario, with manufacturing facilities in Varennes, Quebec and Wanzleben, Germany and a research and development Center in San Diego, California. For more information, please visit www.nuvoresearch.com.

These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but caution that these assumptions regarding future events, many of which are beyond the control of the Company, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations, are discussed in the annual report, as well as in the Company's Annual Information Form for the year ended December 31, 2007. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether a result of new information or future events, except as required by law. For additional information on risks and uncertainties relating to these forward-looking statements, investors should consult the Company's ongoing quarterly filings, annual report and Annual Information Form and other filings found on SEDAR at www.sedar.com.

Summary financial statements attached:

                         CONSOLIDATED BALANCE SHEETS

                                                         As at         As at
                                                   December 31,  December 31,
    (thousands of Canadian dollars)                       2008          2007
                                                             $             $
    -------------------------------------------------------------------------
    ASSETS
    CURRENT
    Cash and cash equivalents                           15,219        21,791
    Accounts receivable                                  2,294         1,802
    Other receivable                                         -           579
    Inventories                                          1,393         1,042
    Prepaid expenses and other                             446           789
    -------------------------------------------------------------------------
    TOTAL CURRENT ASSETS                                19,352        26,003

    Restricted cash                                         93            79
    Property, plant and equipment                        1,990         2,475
    Intangible assets                                        -            90
    -------------------------------------------------------------------------
    TOTAL ASSETS                                        21,435        28,647
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------

    LIABILITIES AND SHAREHOLDERS' EQUITY
    CURRENT
    Accounts payable and accrued liabilities             2,736         2,994
    Short-term loan                                          -           587
    Deferred revenue                                     2,241         1,211
    Current portion of long-term debt
     and capital lease obligations                         181            94
    Current portion of debentures                            -           500
    -------------------------------------------------------------------------
    TOTAL CURRENT LIABILITIES                            5,158         5,386
    Deferred revenue                                     3,321         5,169
    Long-term debt and capital lease obligations           320           222
    Debentures                                           4,774         2,006
    -------------------------------------------------------------------------
    TOTAL LIABILITIES                                   13,573        12,783
    -------------------------------------------------------------------------

    SHAREHOLDERS' EQUITY
    Common shares                                      189,603       187,877
    Warrants                                            10,847        11,243
    Contributed surplus                                  6,890         5,670
    Accumulated other comprehensive income                 114           114
    Deficit                                           (199,592)     (189,040)
    -------------------------------------------------------------------------
    TOTAL SHAREHOLDERS' EQUITY                           7,862        15,864
    -------------------------------------------------------------------------
    TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY          21,435        28,647
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------



       CONSOLIDATED STATEMENTS OF LOSS, COMPREHENSIVE LOSS AND DEFICIT

                                                    Year ended    Year ended
                                                   December 31,  December 31,
    (thousands of Canadian dollars                        2008          2007
     except per share and share amounts)                     $             $
    -------------------------------------------------------------------------
    REVENUE

    Product sales                                        8,008         5,933
    Cost of goods sold                                   4,809         4,391
    -------------------------------------------------------------------------
    Gross margin on product sales                        3,199         1,542

    Other revenue

    Licensing fees                                       2,514         1,000
    Research and other contract revenue                    205           245
    -------------------------------------------------------------------------
                                                         5,918         2,787
    EXPENSES

    Research and development                             9,263         8,319
    Selling, general and administrative expenses         5,204         5,498
    Stock-based compensation                               803           808
    Amortization of property, plant, and equipment
     and intangibles and impairment of intangibles)      1,068           869
    Foreign currency gain                                  (93)         (118)
    Interest expense                                     1,283         1,102
    Interest income                                       (497)         (779)
    -------------------------------------------------------------------------
                                                        17,031        15,699
    -------------------------------------------------------------------------
    Loss from operations                               (11,113)      (12,912)

    Change in estimate in contingency                      860             -
    Loss on extinguishment of convertible debenture       (299)            -
    Gain on sale of assets                                   -           536
    -------------------------------------------------------------------------
    NET LOSS AND TOTAL COMPREHENSIVE LOSS              (10,552)      (12,376)

    Deficit, beginning of year                        (189,040)     (176,664)
    -------------------------------------------------------------------------
    DEFICIT, END OF YEAR                              (199,592)     (189,040)
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
    Net loss per common share - basic and diluted       $(0.04)       $(0.05)
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
    Average number of common shares outstanding -
     basic and diluted (millions)                        306.3         243.1
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------



                    CONSOLIDATED STATEMENTS OF CASH FLOWS

                                                    Year ended    Year ended
                                                   December 31,  December 31,
    (thousands of Canadian dollars)                       2008          2007
                                                             $             $
    -------------------------------------------------------------------------
    OPERATING ACTIVITIES

    Net loss                                           (10,552)      (12,376)
    Items not involving current cash flows:
      Amortization and impairment charge                 1,068           869
      Deferred revenue recognized                       (1,832)       (1,285)
      Stock-based compensation and payments                815           940
      Accretion of interest on debentures                  828           665
      Loss on extinguishment of convertible debenture      299             -
      Change in estimate in contingency                   (860)            -
      Gain on sale of assets                                 -          (536)
      Other                                                (44)         (345)

    Net change in non-cash working capital                 149          (211)
    Proceeds from licensing arrangements
     and advances on research contracts                  1,014            11
    -------------------------------------------------------------------------
    CASH USED IN OPERATING ACTIVITIES                   (9,115)      (12,268)
    -------------------------------------------------------------------------
    INVESTING ACTIVITIES

    Investment in term deposits with restricted use          -           (79)
    Acquisition of property, plant and equipment          (151)         (222)
    Proceeds from the sale of assets                        28             -
    -------------------------------------------------------------------------
    CASH USED IN INVESTING ACTIVITIES                     (123)         (301)
    -------------------------------------------------------------------------
    FINANCING ACTIVITIES

    Issuance of common shares and warrants,
     net of related costs                                1,115        23,854
    Issue of debentures, net of related costs            1,956             -
    Costs related to the November 2004 Unsecured
     Convertible Debenture amendments                      (32)            -
    Repayments of debentures, long-term
     debt and capital lease obligations                   (630)         (675)
    -------------------------------------------------------------------------
    CASH PROVIDED BY FINANCING ACTIVITIES                2,409        23,179
    -------------------------------------------------------------------------
    Effect of exchange rate changes
     on cash and cash equivalents                          257           (32)
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
    Net increase (decrease) in cash and
     cash equivalents during the year                   (6,572)       10,578
    Cash and cash equivalents, beginning of year        21,791        11,213
    -------------------------------------------------------------------------
    CASH AND CASH EQUIVALENTS, END OF YEAR              15,219        21,791
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
    Interest paid                                          256           299
    -------------------------------------------------------------------------


'/>"/>
SOURCE Nuvo Research Inc.
Copyright©2009 PR Newswire.
All rights reserved


Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/7/2016)... ... February 07, 2016 , ... ... empowers employers and organizations with the tools and information to lower the costs, ... to cut the cost of providing employee healthcare benefits by as much as ...
(Date:2/6/2016)... St. Petersburg, FL (PRWEB) , ... February 06, 2016 , ... ... AsSeenOnTV.pro are pleased to announce the launch of a new DRTV campaign with Belly ... rug. If having tried everything from sprays to puppy pads and find nothing works, ...
(Date:2/5/2016)... UT (PRWEB) , ... February 05, 2016 , ... Today, ... Nutrition , announced that the much-anticipated feature with author Jahnavi Foster, specialist in healthy ... Amateur TV Network. , Each week, on his weekly Whole-Food Warrior TV show, Frank ...
(Date:2/5/2016)... York, New York (PRWEB) , ... February 05, 2016 , ... ... life? The answer may be at the tips of your toes. Foot massage, whether ... as well as pure comfort and relaxation. The American Board of Multiple Specialties ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... franchises from across the country gathered at the La Valencia Hotel in San ... PROSHRED Chicago was named the year’s most outstanding franchise, walking away with ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... 2016  Despite the recent explosion in Big Data, ... to embrace Big Data due to the inherent costs ... side, organizations have begun looking to Big Data as ... adherence. --> --> ... LLC, Big Data has started informing many decisions. In ...
(Date:2/5/2016)... , Feb. 5, 2016  ivWatch, a medical devices ... Outstanding STEM Award granted by Governor Terry McAuliffe,s ... Innovation on February 25th at an event to be held ... The STEM award honors professionals and business that have made ... Logo - http://photos.prnewswire.com/prnh/20160205/330117LOGO ...
(Date:2/5/2016)... , Feb. 5, 2016 ... addition of the "Global Musculoskeletal Partnering ... company profile to their offering. ... addition of the "Global Musculoskeletal Partnering ... company profile to their offering. ...
Breaking Medicine Technology: